Supplementary Figure 1 from Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer Article Swipe
Related Concepts
Denosumab
Blockade
RANKL
Medicine
Oncology
Cancer
Immune modulation
Immune system
Internal medicine
Immunology
Receptor
Osteoporosis
Activator (genetics)
Hewitt Chang
,
Jaqueline Marquez
,
Brandon K. Chen
,
Daniel M. Kim
,
Michael L. Cheng
,
Eric Liu
,
Hai Yang
,
Li Zhang
,
Meenal Sinha
,
Alexander Cheung
,
Serena S. Kwek
,
Eric D. Chow
,
Mark Bridge
,
Rahul Aggarwal
,
Terence W. Friedlander
,
Eric J. Small
,
Mark S. Anderson
,
Lawrence Fong
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1158/2326-6066.25540821
· OA: W4393933930
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1158/2326-6066.25540821
· OA: W4393933930
<p>Supplementary Figure 1: Manual gating strategy A representative patient sample was used to illustrate the gating strategy on Cytobank to create pre-determined landmark nodes for scaffold analysis and clustering.</p>
Related Topics
Finding more related topics…